India's next medical frontier is measured in billionths of a metre — and the government is betting big on it. Union Science and Technology Minister Dr. Jitendra Singh addressed the World Congress on Nanomedicine 2026 at Vigyan Bhawan, New Delhi on Sunday, 27 September 2026, laying out a sweeping vision for how nanotechnology will reshape medicine from the cellular level up.

₹174 crore and 200-plus projects: DBT's nanomedicine wager

The headline number from the Congress is striking: the Department of Biotechnology (DBT), under the Ministry of Science and Technology, is currently supporting over 200 R&D projects in nanomedicine with a combined financial outlay of ₹174 crore. That is not a single flagship scheme but a sprawling portfolio — targeted drug delivery, cancer nanomedicine, infectious-disease applications, vaccine delivery platforms, and nano-diagnostics all fall under the umbrella.

Two projects in particular signal how specific — and how ambitious — the research agenda has become: a programme on Nano Oral Insulin that could eventually spare diabetic patients the needle, and the development of nanobots for breast cancer treatment, a technology that would navigate the body at the cellular scale to attack tumours with precision that conventional chemotherapy cannot match.

Why 'one-billionth of a metre' is the new unit of medical progress

Dr. Jitendra Singh framed nanomedicine not as a niche research curiosity but as the engine of the next medical paradigm. 'Nanomedicine involves the application of nanotechnology in medicine, working with structures at the scale of one-billionth of a metre,' he said, adding that it is 'one of the most transformative recent developments in medical practice.'

The minister drew a direct line from nanotechnology to personalised healthcare: 'The future of medicine will increasingly involve individualised treatment based on a patient's genetic profile, lifestyle, dietary habits and environmental factors, with nanotechnology offering new possibilities for precision at the cellular level.' In short, nanomedicine is the infrastructure layer on which precision medicine will be built.

A policy lineage stretching back to 2007

India's commitment to nanotechnology in healthcare did not begin with this Congress. The Department of Science and Technology launched the National Mission on Nano Science and Technology in 2007, seeding an ecosystem of research that DBT has since expanded into clinical applications. The 2026 Congress at Vigyan Bhawan — a venue that has hosted some of India's most consequential scientific summits — marks a checkpoint in that nearly two-decade arc, one at which the country can point to a funded, structured project pipeline rather than aspirational blueprints.

The broader pattern is consistent: successive governments have scaled R&D support in frontier life-science areas, and nanomedicine has benefited from that institutional momentum. Biotech researchers, oncologists, pharma companies developing next-generation therapeutics, and — most consequentially — cancer and diabetes patients stand to be shaped by the outcomes of those 200-plus funded projects.

What follows the Congress

The immediate question is whether the 2026 gathering produces binding commitments: publication timelines for DBT project outcomes, follow-on funding announcements, or international collaborations forged on the Vigyan Bhawan floor. The Minister's public articulation of the vision at a global platform raises the stakes for delivery — India has now told the world what it intends to build, one nanometre at a time.